Public biotech in 2017—the numbers

Article metrics

Last year, investors scrambled to invest in newly floated biotechs. This, together with a brisk licensing market and policy tailwinds, helped boost the sector, even as an expected M&A boom was late to materialize.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: NASDAQ biotech index over time.
Figure 2: Public biotech barometers.
Figure 3: IPO activity since 2004 showing amount raised ($ millions) and number of companies floated.
Figure 4: Global biotech industry financing over the past five years.


  1. 1

    Morrison, C. Fresh from the biotech pipeline—2017. Nat. Biotechnol. 36, 131–136 (2018).

  2. 2

    Dolgin, E. Epic $12 billion deal and FDA's approval raise CAR-T to new heights. Nat. Biotechnol. 35, 891–892 (2017).

  3. 3

    FTC. Mallinckrodt will pay $100 million to settle FTC, state charges it illegally maintained its monopoly of specialty drug used to treat infants. (Federal Trade Commission, 18 January 2017).

  4. 4

    Garber, K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat. Rev. Drug Discov. 17, 227–229 (2018).

  5. 5

    Morrison, C. Alnylam prepares to land first RNAi drug approval. Nat. Rev. Drug Discov. 17, 156–157 (2018).

  6. 6

    Ellis, S. To keep biotechs trading at home, China pilots new stock market rules. Nat. Biotechnol. 36, 384 (2018).

Download references

Author information

Supplementary information

Supplementary Table 1

List of publicly traded biotechs (XLS 226 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Morrison, C., Lähteenmäki, R. Public biotech in 2017—the numbers. Nat Biotechnol 36, 576–584 (2018) doi:10.1038/nbt.4175

Download citation

Further reading